Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Medication Adherence in Schizophrenia: Development of a CBT-Based Intervention

13 giugno 2014 aggiornato da: Peter Weiden, University of Illinois at Chicago
This is a randomized pilot study of an intervention based on principles of Cognitive Behavioral Therapy (CBT). This intervention is the Health Dialogue Intervention (HDI) and will be compared to a traditional medical model of psychoeducation known as Team Solutions (TS) for first-episode schizophrenia patients. Outcomes include the acceptance of HDI and TS, compare adherence attitudes at the end of the treatment intervention, and to compare the time until the first episode of nonadherence.

Panoramica dello studio

Stato

Completato

Descrizione dettagliata

Overview: Many people recovering from first-episode schizophrenia typically respond very well to their initial course of antipsychotic medications; however, studies indicate that nonadherence rates soar as high as 90% in the first year and do not improve over time. To date, there is no effective psychosocial intervention that improves adherence or reduces the adverse consequences of nonadherence after it occurs. Thus, it is imperative to develop a new intervention to improve medication adherence and improve clinical outcomes in patients recovering from first-episode schizophrenia.

This study is to pilot an intervention specifically suited for patients with first-episode schizophrenia based on the principles of Cognitive Behavioral Therapy (CBT). This is to focus on adherence from the perspective of the patient.

Methods: This study compares the effectiveness of a standard psychoeducation program [Team Solutions (TS)] to a CBT approach known as the Health Dialogue Intervention (HDI). Consenting patients will receive a 4 week stabilization assessment period and then be randomized to a prospective, random-assignment study comparing the effectiveness of TS to HDI to improve medication adherence of patients recovering from first-episode schizophrenia.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

34

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Illinois
      • Chicago, Illinois, Stati Uniti, 60612
        • University of Illinois at Chicago

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 16 anni a 45 anni (Bambino, Adulto)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

There is a 2 step inclusion/exclusion criteria, the first being for assessing overall eligibility to enter the study, and then, for continued outpatient treatment for schizophrenia, schizophreniform disorder, or schizoaffective disorder.

Inclusion criteria for entry into the Evaluation Phase:

  1. Between 16-45 years of age
  2. A provisional clinical diagnosis of schizophreniform disorder, schizophrenia, or schizoaffective disorder in last 6 months
  3. Discharge from inpatient unit for treatment of psychotic symptoms must have occurred in the last 6 months, or, if never hospitalized, initial treatment started in the last 6 months
  4. Able to fully participate in the informed consent process
  5. The patient is judged to be an appropriate candidate for ongoing outpatient follow-up at the First-episode Treatment Program at the Psychotic Disorders Program at UIC

Exclusion criteria for the Evaluation Phase:

  1. Unable to understand informed consent process
  2. A history of nonresponse to prior antipsychotic trials such that long-term inpatient treatment or clozapine will be recommended
  3. Prior treatment with clozapine
  4. Discharge from inpatient treatment for psychotic symptoms, initial treatment, or provisional diagnosis of schizophrenia, schizoaffective disorder, or schizophreniform occurred more than 6 months from enrollment into the evaluation phase
  5. Pregnancy or stated goal to become pregnant
  6. Will not be living close enough to the medical center to return for follow-up visits or assessments
  7. History of geographic instability such that it is judged unlikely that patient will reside in the area
  8. Currently under arrest for a felony, or an arrest is deemed likely in the near future
  9. Currently receiving medication over objection by court order
  10. Currently receiving treatment in another research protocol

Inclusion Criteria for the Treatment Intervention Phase:

  1. Willingness to transition to receive evaluation and future pharmacologic treatment at the Psychotic Disorders Program at UIC
  2. Has capacity to understand the risks and benefits of participating in a randomized psychosocial trial
  3. Willingness to sign informed consent to go into the Treatment Intervention Phase
  4. Is able to complete a post-test for understanding the nature of the study and what it entails, and the potential risks and benefits of study participation
  5. Is willing to have therapy sessions recorded for fidelity assessments
  6. Is willing to receive follow-up independent assessments of adherence status, including separate interviews with trained independent raters, and our contacting the outpatient pharmacy for pharmacy refill records

Exclusion criteria for Treatment Intervention Phase:

  1. Diagnosis or inpatient treatment for psychotic symptoms occurred more than 6 months from date of enrollment into evaluation phase
  2. Acutely psychotic individuals may not participate because therapy will not benefit if symptoms are too severe
  3. Has dropped out of the treatment program and cannot be located for follow-up appointments
  4. Stated refusal to come for to at least one clinical evaluation appointment at the PDP, or has been a "no show" for at least three consecutive appointments
  5. Judged to be at significant and imminent risk of harm to self or others*
  6. Ongoing active substance or alcohol use that is not controlled during the Evaluation Phase, along with refusal of referral to a "dual diagnosis" treatment program for substance abuse problems
  7. Remains enrolled in another research protocol at UIC*
  8. Unwilling to consider any additional psychotherapeutic intervention above and beyond coming in to the service for medication management appointment
  9. Baseline PANSS total score ≥ 90, or has a individual PANSS item of conceptual disorganization (item P2), excitement (P4), or hostility (P7) that is ≥ 5 (moderately severe)*
  10. Judged to require additional concrete case management services to support medication adherence*
  11. Receives antipsychotics under coercive conditions (e.g. inpatient or outpatient commitment)*

Note: The exclusion criteria (*) may be present during some parts of the Evaluation Phase and would need to be resolved within the 4 week time period permitted for the Evaluation Phase prior to the Treatment Intervention Phase of study entry.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Triplicare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: CBT
UK-based intervention
Brief intervention of Cognitive Behavioral Therapy sessions compared to Team Solutions

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Lasso di tempo
1. Acceptance of therapeutic intervention as measured by number of sessions attended. 2. Difference in adherence behavior as measured by duration of antipsychotic treatment during follow up (ASV). 3. Differences in adherence attitudes (ROMI).
Lasso di tempo: Completion of Study
Completion of Study

Misure di risultato secondarie

Misura del risultato
Lasso di tempo
1. Compare the course of symptoms and relapse of patients in HDI to those in the TS.
Lasso di tempo: Completion of Study
Completion of Study

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Peter J. Weiden, M.D., University of Illinois at Chicago

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio

1 novembre 2009

Completamento primario (Effettivo)

1 dicembre 2012

Completamento dello studio (Effettivo)

1 marzo 2013

Date di iscrizione allo studio

Primo inviato

18 settembre 2009

Primo inviato che soddisfa i criteri di controllo qualità

18 settembre 2009

Primo Inserito (Stima)

21 settembre 2009

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Stima)

16 giugno 2014

Ultimo aggiornamento inviato che soddisfa i criteri QC

13 giugno 2014

Ultimo verificato

1 giugno 2014

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • R34MH080978 (Sovvenzione/contratto NIH degli Stati Uniti)
  • R34MH080978-01A2 (Sovvenzione/contratto NIH degli Stati Uniti)
  • DSIR 83-AT

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Prove cliniche su Cognitive Behavioral Therapy

3
Sottoscrivi